Scholar Rock Holding (SRRK) Operating Expenses (2017 - 2026)
Scholar Rock Holding's quarterly Operating Expenses came in at $102.0 million in Q1 2026, up 32.33% year-on-year from $77.1 million in Q1 2025, and up 11.01% quarter-over-quarter from $91.9 million in Q4 2025.
Scholar Rock Holding has reported Operating Expenses for 10 years, with the latest figure at $102.0 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 32.33% year-over-year to $102.0 million; the trailing twelve-month figure through Mar 2026 stood at $409.6 million (up 51.29% YoY), and the FY2025 full-year result was $384.6 million, up 52.6% from the prior year.
- Operating Expenses for Q1 2026 stood at $102.0 million, up from $91.9 million in the prior quarter.
- The five-year high for Operating Expenses was $112.1 million in Q2 2025, with the low at $39.1 million in Q2 2023.
- Average Operating Expenses over 5 years is $63.4 million, with a median of $58.4 million recorded in 2024.
- Year-over-year, Operating Expenses fell 9.42% in 2023 and jumped 88.42% in 2025.
- Tracing SRRK's Operating Expenses over 5 years: stood at $40.4 million in 2022, then climbed by 18.81% to $48.0 million in 2023, then soared by 44.4% to $69.4 million in 2024, then soared by 32.5% to $91.9 million in 2025, then grew by 11.01% to $102.0 million in 2026.
- The last three Operating Expenses figures came in at $102.0 million (Q1 2026), $91.9 million (Q4 2025), and $103.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 102.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.02 Mn |
| Dec 31, 2025 | 91.90 Mn |
| Sep 30, 2025 | 103.55 Mn |
| Jun 30, 2025 | 112.11 Mn |
| Mar 31, 2025 | 77.09 Mn |
| Dec 31, 2024 | 69.36 Mn |
| Sep 30, 2024 | 64.78 Mn |
| Jun 30, 2024 | 59.50 Mn |
| Mar 31, 2024 | 58.42 Mn |
| Dec 31, 2023 | 48.03 Mn |
| Sep 30, 2023 | 43.67 Mn |
| Jun 30, 2023 | 39.08 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 40.43 Mn |
| Sep 30, 2022 | 43.86 Mn |
| Jun 30, 2022 | 43.15 Mn |
| Mar 31, 2022 | 40.13 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 42.54 Mn |
| Jun 30, 2021 | 34.87 Mn |
| Mar 31, 2021 | 31.92 Mn |
| Dec 31, 2020 | 29.54 Mn |
| Sep 30, 2020 | 26.66 Mn |
| Jun 30, 2020 | 23.36 Mn |
| Mar 31, 2020 | 22.72 Mn |
| Dec 31, 2019 | 19.92 Mn |
| Sep 30, 2019 | 21.88 Mn |
| Jun 30, 2019 | 18.43 Mn |
| Mar 31, 2019 | 14.81 Mn |
| Dec 31, 2018 | 15.56 Mn |
| Sep 30, 2018 | 11.23 Mn |
| Jun 30, 2018 | 14.88 Mn |
| Mar 31, 2018 | 9.02 Mn |
| Dec 31, 2017 | 8.46 Mn |
| Sep 30, 2017 | 5.94 Mn |
| Jun 30, 2017 | 5.89 Mn |